Forbes December 23, 2024
Global cost pressures and a fast-changing political and regulatory landscape indicate that the pharmaceutical industry is at an inflection point as we head into 2025, as we outline in our recently published Numerof & Associates 2025 Global Pharma Outlook.
To navigate this increasingly complex environment, manufacturers must fundamentally rethink their models, focusing on long-term value, evidence-based decision-making and strategic collaboration.
At a macro level, the single biggest factor in the current landscape is continuing pressure from both government and private payers to reduce the cost and ensure the value of drugs. Across the globe, government payers are raising the bar for market entry. This takes the form of increasing evidentiary requirements and growing complexity in rules that govern reimbursement.
This...
Today's Sponsors
Today's Sponsor